Company intelligence / Profile preview

Nuclera

Cambridge, Cambridgeshire, United Kingdomnuclera.com ↗

Ownership: Private
Development stage: Commercial

Overview

Nuclera has commercialized the eProtein Discovery™ system, enabling rapid benchtop access to high-quality, soluble proteins from DNA in under 48 hours. The system integrates cell-free protein synthesis and digital microfluidics for automated construct screening and purification. It supports drug discovery workflows by allowing scientists to rapidly prototype and obtain target proteins for research. No clinical results as it does not develop therapeutics.

Modalities: ProteinCell-free protein synthesis
Industry: Non-Drug Biotech

Partnerships

E Ink

Beyond the preview

Go deeper on Nuclera.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nuclera.

Explore the full profile